Revenue Breakdown
Composition ()
No data
Revenue Streams
Progyny Inc (PGNY) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Fertility benefits services revenue, accounting for 64.4% of total sales, equivalent to $201.95M. Another important revenue stream is Pharmacy benefits services revenue. Understanding this composition is critical for investors evaluating how PGNY navigates market cycles within the Managed Healthcare industry.
Profitability & Margins
Evaluating the bottom line, Progyny Inc maintains a gross margin of 23.24%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 6.87%, while the net margin is 4.42%. These profitability ratios, combined with a Return on Equity (ROE) of 11.37%, provide a clear picture of how effectively PGNY converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, PGNY competes directly with industry leaders such as PAYO and CBZ. With a market capitalization of $2.06B, it holds a significant position in the sector. When comparing efficiency, PGNY's gross margin of 23.24% stands against PAYO's 78.36% and CBZ's 12.99%. Such benchmarking helps identify whether Progyny Inc is trading at a premium or discount relative to its financial performance.
